Mankind Pharma Q2 profit rises 38% to Rs 716 crore

New Delhi: Mankind Pharma on Monday posted a 37.7% rise in profit to ₹716 crore in the September quarter, driven by strong business growth in domestic and international markets.

Read more: Paytm Q2 Results: Profit rockets 976% YoY to Rs 226 crore, revenue jumps 28%

The company had posted a profit after tax (PAT) of ₹520.2 crore in the year-ago period, according to a regulatory filing. Revenue from operations increased to ₹4,337.9 crore during the quarter under review as against ₹3,697.2 crore in the year-ago period, the company said in a regulatory filing.


Read more: Tata Consumer Q2 Results: Net profit rises 16% YoY to Rs 470 crore, revenue up 14%

"Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth," vice chairman & managing director Rajeev Juneja said.